Oncolytics Biotech® Inc. Meets Primary Endpoint for First Part of U.S. Phase II Pancreatic Cancer Clinical Trial Oncolytics Biotech Inc. announced preliminary results from a U.S. Phase II clinical trial (REO 017) using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. [Oncolytics Biotech Inc. Press Release] Takeda Enrolls Clinical Trial Subject in Phase III Study of Alogliptin in China Takeda Pharmaceutical Company Ltd. and its wholly-owned subsidiary, Takeda Global Research & Development Center Asia, announced the commencement of enrollment for alogliptin for the treatment of type 2 diabetes mellitus in the company’s Phase III clinical trial led out of China. [Takeda Pharmaceutical Company Ltd. Press Release] Targacept Announces Initiation of Phase II Studies of TC-6987 in Asthma and Type 2 Diabetes Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, announced the initiation of separate Phase II clinical studies of its product candidate TC-6987 in disorders characterized by inflammation, one in asthma and one in type 2 diabetes. [Targacept, Inc. Press Release] Last Patient Completes the EU Phase III Study of Diamyd® Antigen Based Therapy for Type 1 Diabetes The final patient has performed the last visit of the main study period in Diamyd Medical’s European Phase III study. Treatment with the antigen based therapy Diamyd® is made to investigate whether beta cell function and thereby blood sugar control can be preserved in children and adolescents with new onset type 1 diabetes. [Diamyd Medical AB Press Release] UMASS Medical School’s Human Stem Cell Bank Makes Available First Seven Stem Cell Lines The first seven stem cell lines grown and banked at the University of Massachusetts (UMASS) Medical School’s Human Stem Cell Bank are ready for worldwide distribution to researchers working on discovering new therapeutic treatments for diseases such as cancer, juvenile diabetes, Alzheimer’s and Parkinson’s, among others. [EurekAlert!] Joslin’s Latino Diabetes Initiative Unveils Enhanced Website Latinos are twice as likely to develop diabetes as Caucasians, and half the Latinos born in the United States in this century are predicted to get the disease. Helping to meet this challenge, Joslin’s Latino Diabetes Initiative has upgraded its website with additional resources for Latinos with diabetes and their families in both English and Spanish. [Joslin Diabetes Center Press Release] Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial consequences, such as cancer and Alzheimer’s disease, according to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company. [Eli Lilly and Company Press Release] |